Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
GLYCOLAX vs COLPREP KIT
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Osmotic laxative. Polyethylene glycol (PEG) increases intraluminal water volume in the colon by osmosis, promoting stool passage and relieving constipation.
Col Prep Kit contains polyethylene glycol (PEG) 3350 and electrolytes (sodium sulfate, potassium sulfate, magnesium sulfate). PEG is an osmotic agent that causes water retention in the colon, increasing stool volume and stimulating bowel movements. Electrolytes maintain fluid and electrolyte balance, preventing shifts during bowel cleansing.
Treatment of occasional constipation
Bowel cleansing prior to colonoscopy
17 g (1 heaping tablespoon) dissolved in 4-8 ounces of liquid once daily, orally.
Colprep Kit (sodium picosulfate/magnesium oxide/citric acid) for bowel cleansing: Two doses administered orally. First dose: 1 sachet reconstituted in water in the evening prior to colonoscopy. Second dose: 1 sachet on the morning of the procedure, at least 5 hours before the procedure. Each sachet is dissolved in 150 m L water, diluted to a total volume of 500 m L, and consumed over 30-60 minutes followed by additional water.
Not applicable due to negligible systemic absorption; local colonic transit time approximately 2-4 hours.
Not applicable; colonic lavage solution with negligible systemic absorption.
Not metabolized; excreted unchanged in feces.
Polyethylene glycol (PEG) 3350 is minimally absorbed and not metabolized; it is excreted unchanged in feces. Electrolytes are absorbed and excreted renally.
Minimally absorbed; excreted primarily unchanged in feces via osmotic action. Renal excretion negligible (<0.2% absorbed dose).
Primarily fecal as unabsorbed drug; minimal renal excretion (<1%).
Not bound (polyethylene glycol not bound to plasma proteins).
Not applicable; not absorbed systemically.
Not applicable due to minimal absorption; if absorbed, distributes largely in extracellular fluid; Vd negligible.
Not applicable; confined to gastrointestinal lumen.
Oral: <0.2% (systemic absorption negligible); rectal: minimal systemic absorption.
Oral: <0.1% (negligible systemic absorption).
No dose adjustment required, but use with caution in patients with renal impairment due to risk of electrolyte disturbances.
Contraindicated in severe renal impairment (Cr Cl <30 m L/min). No specific dose adjustment for mild-to-moderate impairment; use with caution and ensure adequate hydration.
No dose adjustment required; use standard dosing for patients with hepatic impairment.
No dose adjustment required for mild-to-moderate hepatic impairment. Safety not established in severe hepatic impairment (Child-Pugh C); use with caution.
For children 2-11 years: 8.5 g (1/2 heaping tablespoon) dissolved in 4-8 ounces of liquid once daily; for children 12 years and older: same as adult dosing.
Safety and efficacy not established in pediatric patients (<18 years). No approved pediatric dosing.
Use with caution due to increased risk of electrolyte disturbances and dehydration; consider lower starting dose (e.g., 8.5 g once daily) and monitor electrolytes and fluid status.
No specific dose adjustment. Use with caution due to increased risk of electrolyte disturbances and dehydration; ensure adequate hydration and monitor renal function.
None
No FDA black box warning.
Use beyond 1 week may cause dependence; caution in patients with bowel obstruction, ileus, or gastrointestinal perforation; risk of electrolyte disturbances with prolonged use.
Risk of fluid and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypomagnesemia, seizures).,Cardiac arrhythmias in patients with electrolyte imbalances or prolonged QT interval.,Renal impairment: risk of acute phosphate nephropathy if using sodium phosphate-based products; however, this product contains sulfate and magnesium.,Gastric retention or gastrointestinal obstruction: do not use in patients with ileus, gastric retention, bowel obstruction, or perforation.,Aspiration risk: use with caution in patients with impaired gag reflex or those prone to regurgitation.
Bowel obstruction, ileus, gastrointestinal perforation, toxic colitis, toxic megacolon, known hypersensitivity to PEG.
Gastrointestinal obstruction or ileus,Bowel perforation,Toxic colitis or toxic megacolon,Gastric retention,Known hypersensitivity to any component of the kit
No significant food interactions. May be taken with or without food. Avoid concurrent use with high-fiber foods if bloating occurs, as this may exacerbate symptoms.
Avoid all solid foods, milk, yogurt, and any beverages containing pulp or red/purple coloring. Only clear liquids are permitted: water, clear broth (fat-free), apple juice, white grape juice, clear sodas (e.g., ginger ale), black coffee or tea (no milk or creamer). No alcohol. Ensure no dairy or citrus juices.
Polyethylene glycol 3350 (Glyco Lax) has no known teratogenic effects. Animal studies show no fetal harm. Human data are limited but no increased risk of major congenital malformations has been reported. Use in all trimesters is considered low risk.
Colprep Kit contains polyethylene glycol and electrolytes. Polyethylene glycol is not teratogenic in animal studies; no human studies available. Risk to fetus during all trimesters is considered low due to minimal systemic absorption.
Polyethylene glycol 3350 is minimally absorbed systemically (<0.1%), making excretion into breast milk negligible. The M/P ratio is not defined due to lack of detection in plasma. Likely safe during breastfeeding.
Polyethylene glycol is not absorbed systemically and is unlikely to pass into breast milk. M/P ratio not established. Considered compatible with breastfeeding.
No dose adjustment is typically needed. Pharmacokinetic changes in pregnancy (e.g., increased plasma volume, altered GI motility) are unlikely to affect this non-absorbed agent. Standard adult doses (17 g once daily) remain appropriate.
No dose adjustment required in pregnancy due to minimal systemic absorption. Use caution if maternal comorbidities such as renal impairment or congestive heart failure present.
GLYCOLAX (polyethylene glycol 3350) is an osmotic laxative. Onset of action is 24-48 hours. Not for acute relief of constipation; use for chronic constipation. May take 2-4 days for full effect. Avoid in intestinal obstruction or perforation. Dose can be adjusted to achieve soft stools. Can be mixed with any non-carbonated beverage.
Col Prep Kit contains sodium phosphate monobasic and sodium phosphate dibasic. Use with caution in patients with renal impairment, heart failure, or electrolyte abnormalities due to risk of phosphate nephropathy. Ensure adequate hydration before, during, and after administration. Monitor serum electrolytes, BUN, and creatinine in at-risk patients.
Take once daily, preferably in the morning, mixed in 4-8 ounces of liquid.,Effect may take 2-4 days; do not use for immediate relief.,Do not exceed 7 days of use without consulting a doctor.,Drink plenty of fluids while using this medication.,Notify your doctor if you have severe stomach pain, nausea, vomiting, or if you notice blood in your stool.,Keep out of reach of children.
Take the medication exactly as prescribed, usually as a split dose the day before and the day of the procedure.,Drink plenty of clear liquids (e.g., water, clear broth, apple juice) to prevent dehydration.,Do not eat any solid food while taking this medication; only consume clear liquids.,Expect frequent, watery bowel movements starting within 1-2 hours of the first dose.,Contact your doctor if you experience severe abdominal pain, vomiting, or signs of dehydration (e.g., dizziness, decreased urination).,Stop taking other laxatives or stool softeners unless directed by your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about GLYCOLAX vs COLPREP KIT, answered by our medical review team.
GLYCOLAX is a Osmotic Laxative that works by Osmotic laxative. Polyethylene glycol (PEG) increases intraluminal water volume in the colon by osmosis, promoting stool passage and relieving constipation.. COLPREP KIT is a Osmotic Laxative that works by Col Prep Kit contains polyethylene glycol (PEG) 3350 and electrolytes (sodium sulfate, potassium sulfate, magnesium sulfate). PEG is an osmotic agent that causes water retention in the colon, increasing stool volume and stimulating bowel movements. Electrolytes maintain fluid and electrolyte balance, preventing shifts during bowel cleansing.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between GLYCOLAX and COLPREP KIT depend on the specific clinical indication. These are both Osmotic Laxative agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of GLYCOLAX is: 17 g (1 heaping tablespoon) dissolved in 4-8 ounces of liquid once daily, orally.. The standard adult dose of COLPREP KIT is: Colprep Kit (sodium picosulfate/magnesium oxide/citric acid) for bowel cleansing: Two doses administered orally. First dose: 1 sachet reconstituted in water in the evening prior to colonoscopy. Second dose: 1 sachet on the morning of the procedure, at least 5 hours before the procedure. Each sachet is dissolved in 150 m L water, diluted to a total volume of 500 m L, and consumed over 30-60 minutes followed by additional water.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between GLYCOLAX and COLPREP KIT in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. GLYCOLAX is classified as Category C. Polyethylene glycol 3350 (GlycoLax) has no known teratogenic effects. Animal studies show no fetal harm. Human data are limited but no increased risk of major congenital malformati. COLPREP KIT is classified as Category C. Colprep Kit contains polyethylene glycol and electrolytes. Polyethylene glycol is not teratogenic in animal studies; no human studies available. Risk to fetus during all trimesters. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.